In situ follicular lymphoma: Pathologic characteristics and diagnostic features

Research output: Contribution to journalArticle

Abstract

The diagnosis of in situ follicular lymphoma (FL) is feasible when immunohistochemical characterization is carried out and genetic abnormalities are assessed. We usually use a selected diagnostic panel of antibodies (CD10, CD20, CD23, BCL2, BCL6, and Ki67) in lymph nodes with follicular hyperplasia only when we analyze an unexplained lymphadenopathy. Molecular studies, for example, fluorescence in situ hybridization analysis for t(14;18), are restricted to doubtful cases in which immunohistochemistry data are ambiguous. Immunohistochemically, the involved follicles show strongly positive staining for BCL2 and CD10. The BCL2+ cells are confined only to germinal centers and are not seen in the interfollicular region or elsewhere in the lymph node. The BCL2 staining in the abnormal follicles is notable for its high-level and uniform intensity. In situ FL may be associated with overt FL or with lymphomas other than FL or with other malignancies. The crucial point relies on distinguishing in situ FL arising in asymptomatic patients from cases with presence of lymphoma at the same or other sites. Other open questions remain on the frequency with which in situ FLs occur and the frequency of concomitant systemic disease.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalHematological Oncology
Volume30
Issue number1
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Follicular Lymphoma
Lymphoma
Lymph Nodes
Staining and Labeling
Germinal Center
Fluorescence In Situ Hybridization
Hyperplasia
Immunohistochemistry
Antibodies
Neoplasms

Keywords

  • Diagnosis
  • In situ follicular lymphoma
  • Intrafollicular neoplasia
  • Pathology

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

In situ follicular lymphoma : Pathologic characteristics and diagnostic features. / Carbone, Antonino; Gloghini, Annunziata; Santoro, Armando.

In: Hematological Oncology, Vol. 30, No. 1, 03.2012, p. 1-7.

Research output: Contribution to journalArticle

@article{1e288bc3aa6e437fa02920b050f22559,
title = "In situ follicular lymphoma: Pathologic characteristics and diagnostic features",
abstract = "The diagnosis of in situ follicular lymphoma (FL) is feasible when immunohistochemical characterization is carried out and genetic abnormalities are assessed. We usually use a selected diagnostic panel of antibodies (CD10, CD20, CD23, BCL2, BCL6, and Ki67) in lymph nodes with follicular hyperplasia only when we analyze an unexplained lymphadenopathy. Molecular studies, for example, fluorescence in situ hybridization analysis for t(14;18), are restricted to doubtful cases in which immunohistochemistry data are ambiguous. Immunohistochemically, the involved follicles show strongly positive staining for BCL2 and CD10. The BCL2+ cells are confined only to germinal centers and are not seen in the interfollicular region or elsewhere in the lymph node. The BCL2 staining in the abnormal follicles is notable for its high-level and uniform intensity. In situ FL may be associated with overt FL or with lymphomas other than FL or with other malignancies. The crucial point relies on distinguishing in situ FL arising in asymptomatic patients from cases with presence of lymphoma at the same or other sites. Other open questions remain on the frequency with which in situ FLs occur and the frequency of concomitant systemic disease.",
keywords = "Diagnosis, In situ follicular lymphoma, Intrafollicular neoplasia, Pathology",
author = "Antonino Carbone and Annunziata Gloghini and Armando Santoro",
year = "2012",
month = "3",
doi = "10.1002/hon.993",
language = "English",
volume = "30",
pages = "1--7",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "1",

}

TY - JOUR

T1 - In situ follicular lymphoma

T2 - Pathologic characteristics and diagnostic features

AU - Carbone, Antonino

AU - Gloghini, Annunziata

AU - Santoro, Armando

PY - 2012/3

Y1 - 2012/3

N2 - The diagnosis of in situ follicular lymphoma (FL) is feasible when immunohistochemical characterization is carried out and genetic abnormalities are assessed. We usually use a selected diagnostic panel of antibodies (CD10, CD20, CD23, BCL2, BCL6, and Ki67) in lymph nodes with follicular hyperplasia only when we analyze an unexplained lymphadenopathy. Molecular studies, for example, fluorescence in situ hybridization analysis for t(14;18), are restricted to doubtful cases in which immunohistochemistry data are ambiguous. Immunohistochemically, the involved follicles show strongly positive staining for BCL2 and CD10. The BCL2+ cells are confined only to germinal centers and are not seen in the interfollicular region or elsewhere in the lymph node. The BCL2 staining in the abnormal follicles is notable for its high-level and uniform intensity. In situ FL may be associated with overt FL or with lymphomas other than FL or with other malignancies. The crucial point relies on distinguishing in situ FL arising in asymptomatic patients from cases with presence of lymphoma at the same or other sites. Other open questions remain on the frequency with which in situ FLs occur and the frequency of concomitant systemic disease.

AB - The diagnosis of in situ follicular lymphoma (FL) is feasible when immunohistochemical characterization is carried out and genetic abnormalities are assessed. We usually use a selected diagnostic panel of antibodies (CD10, CD20, CD23, BCL2, BCL6, and Ki67) in lymph nodes with follicular hyperplasia only when we analyze an unexplained lymphadenopathy. Molecular studies, for example, fluorescence in situ hybridization analysis for t(14;18), are restricted to doubtful cases in which immunohistochemistry data are ambiguous. Immunohistochemically, the involved follicles show strongly positive staining for BCL2 and CD10. The BCL2+ cells are confined only to germinal centers and are not seen in the interfollicular region or elsewhere in the lymph node. The BCL2 staining in the abnormal follicles is notable for its high-level and uniform intensity. In situ FL may be associated with overt FL or with lymphomas other than FL or with other malignancies. The crucial point relies on distinguishing in situ FL arising in asymptomatic patients from cases with presence of lymphoma at the same or other sites. Other open questions remain on the frequency with which in situ FLs occur and the frequency of concomitant systemic disease.

KW - Diagnosis

KW - In situ follicular lymphoma

KW - Intrafollicular neoplasia

KW - Pathology

UR - http://www.scopus.com/inward/record.url?scp=79960366619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960366619&partnerID=8YFLogxK

U2 - 10.1002/hon.993

DO - 10.1002/hon.993

M3 - Article

C2 - 21560142

AN - SCOPUS:79960366619

VL - 30

SP - 1

EP - 7

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 1

ER -